Only in the short-run. Within a few quarters, RVNC's Daxxify sales will swamp its dermal-filler sales. Daxxify will also have a much higher profit margin than RVNC's dermal fillers.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”